Based on the submitted application and the supplied documents, the State Institute for Drug Control (Czech Republic) has authorized a clinical trial, phase III, of the medicinal product TFI (Transfer Factor) lyophilized mucoadhesive tablet for buccal-oral administration in January 2025. The new medicinal product is based on the results of AUMED’s own research activities in the field of transfer factors. The purpose of this study will be to confirm the efficacy of the medicinal product TFI by demonstrating superiority over placebo. AUMED, a.s. would like to successfully complete the study and proceed with the registration process of the new medicinal product during this year.
AUMED has received support for the project titled “Development of an Immunization Product for Protection Against the Causative Agent of…
AUMED has received support for the project “Innovation in the Production of Immunological Preparations,” registration number CZ.01.01.01/02/24_051/0004982. The essence of…
Our subsidiary, AUMED Pharma a.s., is expanding the Phage Glow range with two new product lines: ATOPCARE Atopcare is here…
Research projects of Aumed, a.s. are financed by the European Structural Funds and with financial support from the state budget through the Ministry of Industry and Trade. A complete list of all ongoing and completed projects with this support can be found here.
Ministry of Industry and Trade
Program TRIO
European Union
European Regional Development Fund
OP Enterprise and Innovation for Competitiveness
Tel.: +420 603 587 701
Komořanská 326/63, 143 14 Praha - Modřany, Česká republika
(c) 2017, Aumed a.s
